+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Traumatic Brain Injury Therapeutics Market 2019-2023 - Product Image

Global Traumatic Brain Injury Therapeutics Market 2019-2023

  • ID: 4721341
  • Report
  • December 2018
  • Region: Global
  • 118 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Baxter
  • Fresenius
  • Johnson&Johnson Services
  • Novartis
  • Pfizer
  • MORE
TBI is also known as an intracranial injury. It occurs when an external force causes damage to the brain. The high prevalence of TBI globally is because of the increase in the number of falls road accidents, and other causes. In most of these cases people with TBI need to be hospitalized. The prevalence of TBI among various age groups and eternal causes are important driving factors for the global TBI therapeutics market. The traumatic brain injury therapeutics market growth at a CAGR of close to 5% during the forecast period

Market Overview

Array of new drug approvals

The drug development process is a long and expansive process. The number of molecules under development for the treatment of TBI is increasing at a substantial rate because of the rising prevalence of TBI globally.

Preference for substitutes

Most drugs are mostly symptomatic and not curative. The substitutes prove to be more efficient and are preferred among patients. This is expected to pose a challenge to the market.

For the detailed list of factors that will drive and challenge the growth of the traumatic brain injury therapeutics market during the 2019-2023, view this report.

Competitive Landscape

The global traumatic brain injury therapeutics market is extremely fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Baxter
  • Fresenius
  • Johnson&Johnson Services
  • Novartis
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Anticonvulsants - Market size and forecast 2018-2023
  • Anti-anxiety agents - Market size and forecast 2018-2023
  • Anticoagulants - Market size and forecast 2018-2023
  • Analgesics - Market size and forecast 2018-2023
  • Other therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 12: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Baxter
  • Fresenius
  • Johnson & Johnson Services
  • Novartis
  • Pfizer
PART 13: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global CNS therapeutics market
Exhibit 03: Segments of global CNS therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Anticonvulsants - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Anticonvulsants - Year-over-year growth 2019-2023 (%)
Exhibit 22: Anti-anxiety agents - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Anti-anxiety agents - Year-over-year growth 2019-2023 (%)
Exhibit 24: Anticoagulants - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Anticoagulants - Year-over-year growth 2019-2023 (%)
Exhibit 26: Analgesics - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Analgesics - Year-over-year growth 2019-2023 (%)
Exhibit 28: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Other therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 30: Market opportunity by product
Exhibit 31: Customer landscape
Exhibit 32: Market share by geography 2018-2023 (%)
Exhibit 33: Geographic comparison
Exhibit 34: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Americas
Exhibit 38: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in EMEA
Exhibit 41: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in APAC
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Decision framework
Exhibit 01: TBI-related hospitalizations by age group and injury mechanism in US 2006-2010
Exhibit 02: Impact of drivers and challenges
Exhibit 03: Awareness initiatives of TBI
Exhibit 04: Vendor landscape
Exhibit 05: Landscape disruption
Exhibit 06: Vendors covered
Exhibit 07: Vendor classification
Exhibit 08: Market positioning of vendors
Exhibit 09: Baxter - Vendor overview
Exhibit 10: Baxter - Business segments
Exhibit 11: Baxter - Organizational developments
Exhibit 12: Baxter - Geographic focus
Exhibit 13: Baxter - Segment focus
Exhibit 14: Baxter - Key offerings
Exhibit 15: Baxter - Key customers
Exhibit 16: Fresenius - Vendor overview
Exhibit 17: Fresenius - Business segments
Exhibit 18: Fresenius - Organizational developments
Exhibit 19: Fresenius - Geographic focus
Exhibit 20: Fresenius - Segment focus
Exhibit 21: Fresenius - Key offerings
Exhibit 22: Fresenius - Key customers
Exhibit 23: Johnson & Johnson Services - Vendor overview
Exhibit 24: Johnson & Johnson Services - Business segments
Exhibit 25: Johnson & Johnson Services - Organizational developments
Exhibit 26: Johnson & Johnson Services - Geographic focus
Exhibit 27: Johnson & Johnson Services - Segment focus
Exhibit 28: Johnson & Johnson Services - Key offerings
Exhibit 29: Johnson & Johnson Services - Key customers
Exhibit 30: Novartis - Vendor overview
Exhibit 31: Novartis - Business segments
Exhibit 32: Novartis - Organizational developments
Exhibit 33: Novartis - Geographic focus
Exhibit 34: Novartis - Segment focus
Exhibit 35: Novartis - Key offerings
Exhibit 36: Novartis - Key customers
Exhibit 37: Pfizer - Vendor overview
Exhibit 38: Pfizer - Business segments
Exhibit 39: Pfizer - Organizational developments
Exhibit 40: Pfizer - Geographic focus
Exhibit 41: Pfizer - Segment focus
Exhibit 42: Pfizer - Key offerings
Exhibit 43: Pfizer - Key customers
Exhibit 44: Validation techniques employed for market sizing
Exhibit 45: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Baxter
  • Fresenius
  • Johnson&Johnson Services
  • Novartis
  • Pfizer
  • MORE
Global Traumatic Brain Injury Therapeutics Market 2019-2023

The analyst recognizes the following companies as the key players in the global traumatic brain injury therapeutics market: Baxter, Fresenius, Johnson & Johnson Services, Novartis, Pfizer.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the introduction of cell- therapy is expected to drive the growth of the global TBI therapeutics market during the forecast period.”

According to the report, one of the major drivers for this market is the rapid pace of development of new diagnostics techniques gives rise to potential options for therapeutic treatment for TBI. This broadens the scope and reach of the market and will drive the market in the future.

Further, the report states that one of the major factors hindering the growth of this market is the cost of drugs, laboratory tests, rehabilitation treatment and surgery contribute to the high overall treatment cost of TBI.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Baxter
  • Fresenius
  • Johnson&Johnson Services
  • Novartis
  • Pfizer
Note: Product cover images may vary from those shown
Adroll
adroll